COMPANY

Immunophotonics, Inc.

HQ: St. Louis, MO source · immunophotonics.com ↗

Also known as Immunophotonics · 3 sources

Keywords: oncology immuno-oncology Colorectal Cancer Colon Cancer Liver Metastases Rectal Cancer Rectal Cancer With Liver Metastases Colorectal Liver Metastasis Colon Cancer Nonsmall Cell Lung Cancer Soft Tissue Sarcoma IP-001

Location: St. Louis, MO · source · Oct 13, 2026

Other sites: Bern, (subsidiary) source

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Sep 1, 2026 Raise Private equity round — Series C: amount not published, announced Sep 1, 2026. Source: company's own press page. source ↗ · Form D filed Sep 4, 2026 SEC Form D ↗
2026-05 Trial start Phase 2/Phase 3: Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases source ↗
Nov 29, 2022 Trial start Phase 1/Phase 2: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS source ↗

Upcoming milestones

2033-12 (ESTIMATED) · Phase 2/Phase 3 · Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases · NCT07321847

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: amount not published. Last 2 years.

Sep 1, 2026 Private equity round — Series C: amount not published, announced Sep 1, 2026. Source: company's own press page. source ↗ · Form D filed Sep 4, 2026 SEC Form D ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07321847	Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases	Phase 2/Phase 3	Not yet recruiting	2026-05	2033-12 (estimated)
NCT05688280	Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS	Phase 1/Phase 2	Active, not recruiting	Nov 29, 2022	2025-02 (estimated)